Reviewed By:

Clinical Immunology focuses on the immune system’s health. Learn about the diagnosis and treatment of allergies, autoimmune diseases, and immunodeficiencies.

Overview and Definition

Scleroderma, medically termed Systemic Sclerosis (SSc), is a complex, multifaceted autoimmune condition that challenges the boundaries of rheumatology, dermatology, and internal medicine. It is not merely a disease of the skin, although the cutaneous manifestations are often the most visible; rather, it is a chronic, progressive disorder of the connective tissue characterized by a triad of pathogenic processes: vascular injury, autoimmunity, and widespread fibrosis.

The term derives from the Greek words “scleros” (hard) and “derma” (skin), reflecting the hallmark induration that develops as the disease advances. However, the pathology extends deep beneath the surface, potentially affecting the microvasculature and major internal organs, including the heart, lungs, kidneys, and gastrointestinal tract. Unlike many other autoimmune diseases that may fluctuate with flares and remissions, scleroderma often follows a distinct trajectory depending on the specific subtype, requiring a sophisticated, long-term medical strategy to manage.

The Pathogenic Triad

Vascular Injury and Endothelial Dysfunction

The earliest event in the development of scleroderma is often undetectable to the naked eye but occurs at the cellular level within the blood vessels. Injury to the endothelial cells—the lining of the blood vessels triggers a cascade of vasoconstriction and vascular remodeling. This is not simple high blood pressure; it is a structural obliteration of the tiny capillaries that nourish the tissues. The body attempts to repair this damage, but the process becomes dysregulated, leading to the narrowing of vessels and chronic ischemia (lack of oxygen) in the affected tissues. This vascular crisis is what manifests clinically as Raynaud’s phenomenon, often years before any skin changes appear.

Immune Dysregulation and Autoimmunity

In a healthy immune system, safeguards prevent the body from attacking itself. In scleroderma, these safeguards fail. The immune system, specifically T-cells and B-cells, becomes activated against specific nuclear antigens found in the body’s own cells. This autoimmune attack produces autoantibodies that are detectable in the blood and serve as critical markers for diagnosis. This immune activation stimulates the release of profibrotic cytokines chemical messengers that signal the body to repair tissue—even in the absence of external injury, setting the stage for the third pillar of the disease.

Progressive Fibrosis and Collagen Deposition

The ultimate consequence of vascular injury and immune activation is fibrosis. Fibroblasts, the cells responsible for wound healing and structural integrity, transform into myofibroblasts and begin producing excessive amounts of extracellular matrix, particularly Type I and Type III collagen. Typically, collagen provides essential support; in scleroderma, its overproduction turns pliable tissues into stiff, non-functional scar tissue. When this occurs in the skin, it limits mobility; when it happens in the lungs or heart, it compromises organ function and threatens life.

Classification of Scleroderma

Systemic sclerosis is clinically heterogeneous, meaning it looks very different from one patient to another. To manage this variability, the medical community divides the condition into distinct subsets based on the extent of skin involvement, which correlates strongly with the risk of internal organ involvement.

Limited Cutaneous Systemic Sclerosis (lcSSc)

Historically known as CREST syndrome, this subtype is the more common form of the disease. In lcSSc, skin thickening is restricted to the distal extremities—specifically below the elbows and knees and the face and neck. While the skin progression is generally slower and less extensive, this form is deceptive. Patients with lcSSc are at a specifically elevated risk for distinct vascular complications, most notably Pulmonary Arterial Hypertension (PAH), which can develop decades after the onset of the disease. The progression is insidious, often allowing patients to live for many years with symptoms primarily managed as distinct issues before a unifying diagnosis is made.

Diffuse Cutaneous Systemic Sclerosis (dcSSc)

This subtype represents a more aggressive and rapidly progressing form of the disease. Skin thickening spreads proximally, involving the upper arms, thighs, and trunk (chest and abdomen). The speed of skin involvement often correlates with the risk of early and severe internal organ damage. Patients with diffuse disease are at the highest risk for Interstitial Lung Disease (ILD) and Scleroderma Renal Crisis (SRC) within the first three to five years of symptom onset. The “window of opportunity” for treating diffuse disease is narrower, requiring early, aggressive immunosuppressive therapy.

Sine Scleroderma

A rare and diagnostically challenging subset is Systemic Sclerosis Sine Scleroderma. These patients have internal organ involvement, vascular abnormalities, and serological (antibody) markers of systemic sclerosis, but lack the characteristic skin thickening. Because the visible hallmark is absent, these cases are frequently misdiagnosed or diagnosed only after significant organ damage has occurred.

IMMUNOLOGY

Epidemiology and Demographics

Understanding who is at risk for scleroderma helps with early identification. It is a rare disease, with an estimated prevalence that varies globally but typically ranges from 20 to 30 individuals per 100,000.

Gender and Hormonal Influence

There is a profound gender disparity in scleroderma, with women affected four to nine times more frequently than men. This strong female predominance suggests a potential hormonal influence on the disease’s pathogenesis, particularly estrogen-related mechanisms, although the exact mechanism remains under investigation. Interestingly, while men are less likely to develop scleroderma, they often experience a more severe disease course and poorer prognosis when they do.

Age of Onset

The peak age of onset is typically between 30 and 50 years old. However, the disease does not discriminate strictly by age; it can occur in children (Juvenile Systemic Sclerosis) and the elderly (Late-Onset Scleroderma). Juvenile cases tend to focus on localized skin changes rather than systemic organ involvement, whereas late-onset cases often present with a more aggressive internal presentation.

Genetic and Ethnic Susceptibility

While not a directly inherited genetic disease like cystic fibrosis, there is a genetic predisposition. Having a first-degree relative with scleroderma or another autoimmune disease (like lupus or Hashimoto’s thyroiditis) slightly increases risk. Ethnic factors also play a role; for instance, African American patients often have an earlier age of onset and are more prone to the diffuse subtype with severe lung involvement compared to Caucasian patients. Specifically, the Choctaw Native Americans have been identified as having an exceptionally high prevalence of the disease, pointing to specific genetic risk loci.

Environmental Triggers

The “two-hit hypothesis” in autoimmunity suggests that a genetically susceptible individual must encounter an environmental trigger to initiate the disease. Several external factors have been implicated in the development of scleroderma-like conditions.

Occupational Exposures

Prolonged exposure to silica dust is one of the most well-established environmental links. This is often seen in miners, stonemasons, and workers in abrasive blasting. Inhaled silica particles can trigger a localized inflammatory response that cascades into systemic autoimmunity. Similarly, exposure to certain organic solvents used in paint thinners, resins, and dry cleaning (such as trichloroethylene) has been statistically associated with a higher risk of developing the disease.

Drug-Induced Scleroderma

Certain medications have been known to induce scleroderma-like skin changes. Bleomycin, a chemotherapy agent, and pentazocine, an opioid analgesic, have been linked to fibrosis. In recent history, contaminated batches of L-tryptophan supplements caused an outbreak of Eosinophilia-Myalgia Syndrome, a condition with features mimicking scleroderma, highlighting how ingested substances can trigger widespread fibrosis.

Impact on Quality of Life

Scleroderma is more than a clinical diagnosis; it is a life-altering condition. The impact extends beyond physical symptoms to affect psychological well-being, social interactions, and functional independence. The visible nature of the disease—changes in facial appearance, hand deformities, and skin pigmentation can lead to body image distress and social withdrawal. Fatigue, often severe and debilitating, is a nearly universal symptom that is frequently under-addressed. At Liv Hospital, we recognize that defining the disease involves understanding its profound impacts on daily living, ensuring that the condition’s definition includes the patient’s human experience.

Symptoms and Immune Disorders

Symptoms and Risk Factors

The clinical presentation of scleroderma is notoriously protean, meaning it can take many forms and change significantly over time. No two patients will have identical symptom constellations. The disease affects the body in a patchwork fashion, driven by the underlying vascular and fibrotic damage. Recognizing the symptoms requires a systems-based approach, examining the skin, blood vessels, digestive tract, lungs, heart, and kidneys. Understanding the specific risk factors that predispose individuals to these symptoms is equally vital for early intervention and risk stratification.

The Phases of Skin Involvement

Skin involvement in systemic sclerosis typically evolves through three distinct phases, particularly in the diffuse subtype. Understanding these phases helps in monitoring disease activity.

The Edematous Phase

In the early stages, patients often experience painless swelling of the fingers and hands. This is not the hard skin seen later, but rather a “puffy” appearance in which fine wrinkles disappear and rings may become tight. This edema is caused by fluid retention in the tissues due to leaky, damaged microvasculature. Patients may report morning stiffness and a sensation that their skin feels “too tight” in their hands.

The Indurative Phase

IMMUNOLOGY

As the disease progresses, the swelling is replaced by thickening and hardening (induration). The skin becomes shiny and taut, adhering to the underlying subcutaneous tissue, making it difficult to pinch. Hair growth in the affected areas stops, and sweat glands may stop functioning, leading to dry, itchy skin. This phase is characterized by intense collagen deposition.

The Atrophic Phase

After several years, the skin may soften and thin out (atrophy). While this might seem like an improvement, it actually represents the final stage of fibrosis, where the tissue has become fragile. Despite the softening, underlying contractures (permanent joint tightening) may persist if physical therapy has not been maintained.

Vascular Symptoms: The Raynaud’s Spectrum

Vascular dysfunction is almost universal in systemic sclerosis and is often the sentinel symptom.

Primary vs. Secondary Raynaud’s

Raynaud’s phenomenon describes the exaggerated vasospasm of the digital arteries in response to cold or stress. While “Primary Raynaud’s” is common in the general population and benign, “Secondary Raynaud’s” associated with scleroderma is pathological. It is often more severe, leading to critical ischemia. The attacks are more prolonged, more painful, and can occur even with minor temperature drops, such as reaching into a freezer or entering an air-conditioned room.

Digital Ulcers and Pitting Scars

Chronic lack of blood flow leads to tissue death at the fingertips. This manifests as digital ulcers—excruciating, slow-healing open sores that are prone to infection. Over time, repeated ischemia causes “pitting scars,” which are small, depressed areas on the fingertips where tissue has been lost. In severe cases, vascular compromise can lead to gangrene and necessitate amputation.

IMMUNOLOGY

Gastrointestinal Tract Manifestations

The GI tract is the second most commonly involved organ system after the skin, affecting up to 90% of patients. The fibrosis and atrophy of the smooth muscle in the digestive tract lead to hypomotility (slow movement).

Upper GI Symptoms

The esophagus is frequently affected. The lower esophageal sphincter becomes incompetent, allowing acid to reflux into the esophagus (GERD). This is not typical heartburn; it can be severe enough to cause erosive esophagitis and strictures (narrowing), making swallowing solid foods difficult (dysphagia).

Gastric Antral Vascular Ectasia (GAVE)

Also known as “watermelon stomach” due to the striped appearance of blood vessels in the stomach lining, GAVE can cause chronic, silent bleeding, leading to profound anemia.

Lower GI Symptoms

In the small intestine, slowed motility can lead to Small Intestinal Bacterial Overgrowth (SIBO). Stagnant food allows bacteria to proliferate, leading to bloating, diarrhea, and malabsorption of essential nutrients. In the large intestine, hypomotility often results in severe constipation and, in rare cases, pseudo-obstruction.

Pulmonary Manifestations: The Leading Cause of Mortality

Lung involvement is the most critical aspect of modern scleroderma management. There are two primary presentations.

Interstitial Lung Disease (ILD)

ILD involves inflammation and scarring of the lung tissue itself (the interstitium). This creates a barrier to oxygen transfer. Symptoms include a persistent dry cough and dyspnea (shortness of breath) on exertion. It is most common in diffuse cutaneous systemic sclerosis and often presents early in the disease course. “Velcro crackles” can be heard at the lung bases through a stethoscope.

Pulmonary Arterial Hypertension (PAH)

PAH involves high blood pressure in the arteries connecting the heart to the lungs. Unlike ILD, the lung tissue itself remains flexible, but the vessels narrow, straining the right side of the heart. This is more common in the limited cutaneous (CREST) subtype. Symptoms include severe fatigue, breathlessness, and fainting spells (syncope).

Cardiac and Renal Complications

Scleroderma Heart Disease

Fibrosis can affect the heart muscle (myocardium), leading to diastolic dysfunction (stiffness prevents proper filling). It can also affect the electrical conduction system, causing arrhythmias. Pericardial effusions (fluid around the heart) are also seen during active inflammation.

Scleroderma Renal Crisis (SRC)

SRC is a medical emergency characterized by the abrupt onset of malignant hypertension and acute kidney injury. It occurs in 10-15% of patients with diffuse disease. Symptoms include severe headache, blurred vision, seizures, and breathlessness due to flash pulmonary edema. The risk is highest in the early years of the disease and in patients taking high-dose steroids.

Musculoskeletal and Neurological Symptoms

Joint and Tendon Involvement

Arthralgia (joint pain) and arthritis are common. A unique finding in scleroderma is “tendon friction rubs,” a leathery, creaking sensation felt when a patient moves a joint, caused by fibrin deposits on the tendon sheaths. This is a marker of severe diffuse disease.

Neuropathies

While the central nervous system is rarely directly involved, peripheral neuropathies can occur. Trigeminal neuralgia (facial pain) and carpal tunnel syndrome (due to tissue swelling compressing the nerve) are frequent complaints.

Diagnosis and Evaluation

Scleroderma: Diagnosis and Tests

Diagnosing scleroderma requires a detective’s mindset. Because the disease mimics other connective tissue disorders in its early stages, misdiagnosis is common. At Liv Hospital, we employ a rigorous, multi-modal diagnostic protocol that integrates clinical observation with advanced serological and imaging technology. The diagnosis is rarely made by a single “yes or no” test; rather, it is established by fulfilling a set of classification criteria, typically the 2013 ACR/EULAR criteria, which assigns points to various clinical features.

The Autoantibody Profile

The immunological footprint of scleroderma is distinct. Approximately 95% of patients will test positive for Antinuclear Antibody (ANA). However, the ANA pattern and the specific antibodies present provide a roadmap for diagnosis and prognosis.

Anti-Centromere Antibodies (ACA)

These antibodies are strongly associated with Limited Cutaneous Systemic Sclerosis (lcSSc). A positive result here suggests slower skin progression but alerts the clinician to closely monitor for Pulmonary Arterial Hypertension (PAH) in the future.

Anti-Scl-70 (Anti-Topoisomerase I)

This antibody is the hallmark of Diffuse Cutaneous Systemic Sclerosis (dcSSc). Its presence correlates with a higher risk of Interstitial Lung Disease (ILD) and significant skin fibrosis. Patients with this marker require aggressive early monitoring of lung function.

Anti-RNA Polymerase III

This marker identifies a subset of patients at rapid risk for extensive skin thickening and, critically, Scleroderma Renal Crisis (SRC). Identifying this antibody early is vital because it changes the management plan regarding blood pressure monitoring and steroid avoidance

Nailfold Capillaroscopy

IMMUNOLOGY

Nailfold capillaroscopy is a non-invasive, highly sensitive diagnostic tool that differentiates primary Raynaud’s (benign) from secondary Raynaud’s (scleroderma-associated). By placing the finger under a microscope or a dermatoscope, the doctor visualizes the capillary loops.

The “Scleroderma Pattern”

In healthy individuals, capillaries are uniform, hairpin-shaped loops. In scleroderma, specific abnormalities occur:

Giant Capillaries: Enlarged, dilated loops indicating vessel stress.
Hemorrhages: Tiny areas of bleeding where vessels have ruptured.
Avascular Areas: Regions where capillaries have completely disappeared (dropout), indicating advanced vascular damage.

Pulmonary Evaluation: Structural and Functional

Given the high mortality associated with lung disease, pulmonary testing is comprehensive.

High-Resolution Computed Tomography (HRCT)

A standard chest X-ray is insufficient. HRCT provides detailed cross-sectional images of the lungs. Radiologists look for “ground-glass opacities” (indicating active inflammation) or “honeycombing” (indicating permanent fibrosis). This distinction determines whether immunosuppression will be adequate.

Pulmonary Function Tests (PFTs)

PFTs measure the mechanics of breathing. Two values are critical:

FVC (Forced Vital Capacity): Measures lung volume. A decline suggests restriction due to fibrosis.
DLCO (Diffusing Capacity of the Lung for Carbon Monoxide): Measures gas exchange. An isolated drop in DLCO (while FVC remains normal) is a red flag for Pulmonary Hypertension.

IMMUNOLOGY

Cardiac Assessment

Transthoracic Echocardiogram

This ultrasound of the heart is the primary screening tool for Pulmonary Arterial Hypertension. It measures the velocity of the Tricuspid Regurgitation (TR) jet to estimate pressure in the pulmonary arteries. It also assesses the pericardium for fluid and the myocardium for stiffness.

Cardiac MRI

In cases where myocardial fibrosis is suspected, a Cardiac MRI may be ordered. It is more sensitive than an echo in detecting inflammation and scarring within the heart muscle itself.

Gastrointestinal Diagnostics

Esophagogastroduodenoscopy (EGD)

This procedure involves passing a camera down the throat to visualize the esophagus and stomach. It is used to diagnose Candida esophagitis, strictures, Barrett’s esophagus (precancerous changes), and GAVE.

Esophageal Manometry

This test measures the pressure and coordination of the esophageal muscles. In scleroderma, the classic finding is a “hypotensive lower esophageal sphincter” and “absent peristalsis” in the lower two-thirds of the esophagus, confirming the cause of swallowing difficulties.

Hydrogen Breath Testing

To diagnose Small Intestinal Bacterial Overgrowth (SIBO), patients drink a sugar solution and breathe into a specialized machine. Elevated hydrogen or methane levels in the breath indicate that bacteria in the small intestine are fermenting the sugar, confirming malabsorption.

Skin Biopsy

While less common now due to the reliability of antibody testing, a skin biopsy may be performed in atypical cases. A slight punch of skin is removed and examined by a pathologist. The findings of thickened collagen bundles in the reticular dermis, loss of skin appendages (hair follicles, sweat glands), and entrapment of fat cells are definitive for scleroderma. This is particularly useful for ruling out “scleroderma mimics” such as Scleromyxedema or Nephrogenic Systemic Fibrosis.

Assessment of Renal Function

Routine blood tests for creatinine and urea are standard. However, the most critical test for predicting renal crisis is simple blood pressure monitoring. Patients are often asked to keep a home log. Urinalysis is also performed to check for proteinuria (protein in urine) or hematuria (blood in urine), which can indicate early kidney stress.

Treatment and Management

Treatment and Care

The management of scleroderma has undergone a revolution in the last two decades. While the term “cure” remains elusive, “remission” and “disease control” are realistic goals. Treatment at Liv Hospital is organ-based, meaning we deploy specific therapies for specific complications. The strategy is often dual-tracked: vascular therapies to improve blood flow and immunosuppressive therapies to halt inflammation and fibrosis. This requires a dynamic, aggressive approach, usually combining medications to achieve the best outcome.

Vascular Therapies: Combating Ischemia

Treating the vasculopathy is the foundation of care, as poor blood flow drives both symptoms and tissue damage.

Calcium Channel Blockers (CCBs)

Drugs like nifedipine or amlodipine are the first line of defense. They relax the smooth muscles of the blood vessel walls, reducing the frequency of Raynaud’s attacks. Patients are often titrated to the highest tolerable dose.

Phosphodiesterase-5 (PDE-5) Inhibitors

Initially designed for other purposes, drugs like sildenafil and tadalafil are potent vasodilators used in scleroderma. They are particularly effective for healing digital ulcers and are also a mainstay in treating Pulmonary Arterial Hypertension.

Endothelin Receptor Antagonists (ERAs)

Bosentan and ambrisentan block endothelin, a powerful substance made by the body that constricts blood vessels. These are advanced therapies typically reserved for preventing new digital ulcers and treating pulmonary hypertension.

Prostacyclin Analogs

In severe cases where ischemia threatens a digit (gangrene risk) or in advanced pulmonary hypertension, intravenous epoprostenol or iloprost is administered. These mimic the body’s natural vessel dilators and require careful hospital management.

Immunosuppressive Strategies

To stop the body from attacking itself and laying down collagen, the immune system must be modulated.

Methotrexate and Mycophenolate Mofetil (MMF)

Methotrexate is often the first choice for early diffuse skin disease. MMF has become the gold standard for scleroderma-associated Interstitial Lung Disease (SSc-ILD). Clinical trials have shown MMF to be effective in stabilizing lung function with a manageable side-effect profile.

Cyclophosphamide

This is a more potent alkylating agent reserved for severe, rapidly progressive lung disease. Due to higher toxicity risks, it is usually used for a short “induction” period to stop the disease in its tracks, followed by maintenance with MMF.

Biological Therapies

Tocilizumab: An IL-6 inhibitor that has shown promise in preserving lung function in early diffuse systemic sclerosis.
Rituximab: A B-cell depleting therapy used in refractory cases, particularly when there is significant arthritis or lung involvement that doesn’t respond to standard drugs.

Anti-Fibrotic Therapy

Nintedanib

This is a breakthrough medication specifically approved for Scleroderma-associated Interstitial Lung Disease. Unlike immunosuppressants, nintedanib interferes with the fibroblast’s ability to create scar tissue. It has been proven to slow the rate of decline in lung function and is often used in combination with MMF.

IMMUNOLOGY

Hematopoietic Stem Cell Transplantation (HSCT)

For a select group of patients with early, rapidly progressive diffuse scleroderma who are at high risk of organ failure, Autologous Stem Cell Transplantation is a consideration. This procedure involves harvesting the patient’s own stem cells, using high-dose chemotherapy to “wipe out” the dysfunctional immune system, and then rebooting it with the stored stem cells. It carries significant risks but offers the possibility of long-term drug-free remission and improved survival.

Gastrointestinal Management

Proton Pump Inhibitors (PPIs)

High-dose PPIs (e.g., omeprazole, lansoprazole) are non-negotiable for most patients to prevent esophageal scarring.

Prokinetics

Drugs like domperidone or erythromycin help stimulate stomach emptying and intestinal motility, combating bloating and constipation.

Antibiotics

Cyclical courses of antibiotics (e.g., rifaximin, ciprofloxacin) are used to treat Small Intestinal Bacterial Overgrowth (SIBO), reducing diarrhea and improving nutrient absorption.

Renal Crisis Intervention

The treatment for Scleroderma Renal Crisis is specific and counterintuitive to general nephrology. ACE Inhibitors (like captopril or enalapril) are the absolute required treatment. They must be started immediately upon suspicion of a crisis. Interestingly, dialysis may be needed temporarily, but many patients recover kidney function after a year or two of aggressive ACE inhibitor therapy, allowing them to come off dialysis—a phenomenon unique to scleroderma.

Local and Supportive Care

Wound Care

Digital ulcers require meticulous hygiene, protective dressings, and sometimes surgical debridement. Off-loading pressure from the fingertips is essential.

Physiotherapy

Hand therapy is vital to prevent contractures. Paraffin wax baths can help soften the skin before stretching exercises. Mouth stretching exercises are prescribed in order to avoid microstomia (small mouth opening).

Laser Therapy

Pulsed dye laser therapy is effectively used to treat telangiectasias (red spots) on the face, offering significant cosmetic improvement and psychological benefit.

FREQUENTLY ASKED QUESTIONS

What is the difference between scleroderma and systemic sclerosis?

The terms are often used interchangeably, but “scleroderma” strictly refers to the skin condition, while “systemic sclerosis” emphasizes that the disease affects internal organs and systems throughout the body.

Is scleroderma considered a form of cancer?

No, scleroderma is not a type of cancer. It is an autoimmune rheumatic disease. However, autoimmune inflammation can slightly increase the risk of certain malignancies, requiring vigilance.

What causes the skin to become hard?

The hardening is caused by excessive collagen production. The immune system sends false signals to fibroblast cells, telling them to repair an injury that doesn’t exist, leading to a buildup of tough scar tissue.

Can children get scleroderma?

Yes, this is called Juvenile Scleroderma. It differs from the adult form as it is more likely to be localized to the skin (localized scleroderma) and less likely to involve internal organs, though systemic cases do occur.

Is scleroderma fatal?

While it is a serious chronic condition, it is not immediately fatal. Life expectancy depends heavily on the extent of internal organ involvement. With modern treatments, many patients live a normal lifespan, though those with severe lung or kidney involvement face higher risks.

Why do my fingers change color in the cold?

This is Raynaud’s phenomenon. The blood vessels in your fingers spasm and clamp shut to preserve core body heat, cutting off blood flow to the extremities, turning them white and blue.

What is “Watermelon Stomach”?

Medically called GAVE, it is a condition where dilated blood vessels line the stomach in a striped pattern. These vessels are fragile and can bleed, causing anemia.

Can scleroderma affect my teeth?

Yes. Tightening of the facial skin (microstomia) makes dental hygiene difficult. Additionally, widening of the periodontal ligament is a common X-ray finding, and dry mouth (sicca) increases the risk of cavities.

What are the signs of lung involvement?

The earliest signs are often subtle, such as getting out of breath when climbing stairs or a dry, nagging cough that doesn’t go away.

Does scleroderma cause muscle pain?

Yes, it can cause myopathy (muscle weakness) and myositis (muscle inflammation), leading to difficulty in lifting objects or climbing stairs.

Does a positive ANA test mean I have scleroderma?

Not necessarily. A positive ANA is seen in many autoimmune diseases and even in some healthy people. It must be interpreted alongside symptoms and specific scleroderma antibodies.

Is the nailfold capillaroscopy painful?

No, it is entirely painless. It is simply a microscopic view of the skin at the base of your fingernail, using oil and a lens.

Why do I need a heart ultrasound if I have no chest pain?

Pulmonary hypertension can be silent in its early stages. An echo is the only way to screen for it before severe symptoms develop.

How often do I need lung scans?

Typically, HRCT is done at diagnosis. If you have the diffuse subtype or markers for lung disease, it may be repeated periodically, but PFTs (breathing tests) are done more frequently (every 3-6 months).

What is the difference between an X-ray and HRCT?

An X-ray is a 2D image that misses fine details. HRCT produces thin-slice 3D images, allowing doctors to see lung tissue texture and detect very early scarring.

Will I have to take steroids?

Doctors are very cautious with steroids (like prednisone) in scleroderma because high doses can trigger Scleroderma Renal Crisis. If used, they are kept at low doses for short periods.

What is the newest treatment for lung scarring?

Nintedanib is an anti-fibrotic drug recently approved to slow down the scarring process in scleroderma-associated lung disease.

Is a stem cell transplant a cure?

It is not a guaranteed cure, but it can “reset” the immune system and stop disease progression for many years. It is a significant procedure reserved for severe cases.

How do I treat painful fingertip ulcers?

Treatment involves keeping them warm and clean, using vasodilator medications to improve blood flow, and sometimes using specialized dressings. Smoking cessation is critical.

Can diet fix my stomach problems?

While diet can’t cure the fibrosis, eating small, frequent meals, avoiding late-night eating, and reducing fiber (if you have slow motility) can significantly reduce symptoms.

No, scleroderma is not a type of cancer. It is an autoimmune rheumatic disease. However, autoimmune inflammation can slightly increase the risk of certain malignancies, requiring vigilance.